Dr. Reddy’s Laboratories: Basic Information
Full Name: Dr. Reddy’s Laboratories Limited
Type: Public Sector Pharmaceutical Company
Headquarters: Hyderabad, Telangana, India
Founded: 1984
Founder: Dr. Kallam Anji Reddy
Chairman: G.V. Prasad (as of 2025)
CEO & MD: Erez Israeli (as of 2025)
Tagline: Good Health Can’t Wait
Industry: Pharmaceuticals and Biologics
Products and Services:
- Therapeutic Areas: Oncology, dermatology, diabetes, and cardiovascular diseases
- Generic Medicines: Affordable and high-quality formulations
- Specialty Products: Biosimilars, over-the-counter (OTC) drugs, and proprietary medicines
- Active Pharmaceutical Ingredients (APIs): Supplying APIs to pharmaceutical companies worldwide
Key Financial Metrics (as of 2024):
- Revenue: ₹25,000 crore (approx.)
- Net Profit: ₹3,800 crore (approx.)
- Market Capitalization: ₹90,000 crore (approx.)
Global Presence:
- Operations in over 50 countries
- Manufacturing facilities in India, the United States, and Europe
- Strong export portfolio, particularly in the US, Europe, and emerging markets
Recognition:
- Leader in biosimilars and oncology medicines
- Recognized for sustainable manufacturing practices
- Innovator in affordable healthcare and cutting-edge research
Two-Paragraph Introduction
Dr. Reddy’s Laboratories is a globally renowned pharmaceutical company dedicated to delivering affordable and innovative healthcare solutions. Founded in 1984 by Dr. Kallam Anji Reddy and headquartered in Hyderabad, Dr. Reddy’s specializes in a wide range of therapeutic areas, including oncology, dermatology, and diabetes. The company’s robust portfolio includes generic medicines, biosimilars, and proprietary drugs, along with active pharmaceutical ingredients (APIs) that cater to a global clientele. Dr. Reddy’s commitment to quality and innovation has positioned it as a trusted name in pharmaceuticals across over 50 countries.
Just as Reliance has revolutionized the telecom and energy sectors, Dr. Reddy’s Laboratories has transformed the pharmaceutical industry by making advanced therapies accessible to millions. With a focus on patient-centric solutions and sustainable practices, the company addresses some of the world’s most pressing healthcare challenges. Its cutting-edge research and global outreach continue to drive its mission of delivering “Good Health Can’t Wait,” solidifying its status as a leader in affordable and innovative healthcare.